PT  - JOURNAL ARTICLE
AU  - Barry, Ciarrah-Jane S
AU  - Walker, Venexia M
AU  - Burden, Christy
AU  - Smith, George Davey
AU  - Davies, Neil M
TI  - Assessing the benefits and risks to mothers and offspring of continuing treatment for maternal hypertension and hypothyroidism: an observational cohort study in the UK Clinical Practice Research Datalink
AID  - 10.1101/2024.08.09.24311727
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.08.09.24311727
4099  - http://medrxiv.org/content/early/2024/12/06/2024.08.09.24311727.short
4100  - http://medrxiv.org/content/early/2024/12/06/2024.08.09.24311727.full
AB  - AJOG at a glance A. Why was this study conducted?This study aimed to evaluate the risks and benefits of discontinuing maternal prescriptions for chronic hypertension and hypothyroidism during pregnancy.B. What are the key findings?Discontinuing beta-blockers and thyroid hormones was associated with some improved maternal outcomes, such as a reduced risk of miscarriage. We found limited evidence of an association between the discontinuation of multiple drugs subclasses such as renin-angiotensin system drugs and differential risk of maternal or neonatal outcomes.C. What does this study add to what is already known?This study provides observational evidence that discontinuing certain medications may not be strongly associated with differential risk of maternal or neonatal outcomes and highlights the need for further research due to limitations such as confounding by indication and potential data misclassification.Exclusion of pregnant women from clinical trials, due to ethical concerns, has limited evidence on medication safety during pregnancy, resulting in conservative guidance. Yet, rising prevalence of chronic conditions in reproductive-age women has increased medication use. This study evaluates risks and benefits of discontinuing drug prescriptions for chronic hypertension, and hypothyroidism during pregnancy using linked primary care records from a longitudinal intergenerational database.Using UK Clinical Practice Research Datalink (CPRD) GOLD, we conducted multivariable regression models, adjusted for covariates, to assess maternal treatment discontinuation on various outcomes.Cohorts of 3,232 and 3,334 pregnancies with chronic hypertension and hypothyroidism respectively were derived from the CPRD. Discontinuing vasodilator antihypertensive drugs for hypertension was associated with increased gestational age (mean difference: 3.98 weeks, 95% CI: 1.61, 6.35). Estimated associations between other antihypertensives (calcium-channel blockers, diuretics or renin-angiotensin system drugs) and any study outcome crossed the null. Discontinuing thyroid hormones for hypothyroidism were associated with reduced the odds of miscarriage (OR: 0.29, 95% CI: 0.15, 0.54) and increased gestational age (mean difference 1.84 weeks, 95% CI: 0.12, 3.57). Results were robust in sensitivity analysis.This study reports a reassuring lack of association between many drug subclasses and adverse offspring outcomes. This evidence of potential risk associated with treatment discontinuation may guide clinical decision-making for treating chronic hypertension and hypothyroidism during pregnancy in similar populations.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://wellcomeopenresearch.org/articles/7-12 Funding StatementThis work was supported by the Medical Research Council (MRC) and the University of Bristol MRC Integrative Epidemiology Unit (MC_UU_00011/1, MC_UU_00011/4). CJSB is supported by a Wellcome Trust PhD studentship (218495/Z/19/Z). NMD is supported by the Research Council of Norway (295989). VW is supported by the COVID-19 Longitudinal Health and Wellbeing National Core Study, which is funded by the Medical Research Council (MC_PC_20059) and NIHR (COV-LT-0009 and the Medical Research Council Integrative Epidemiology Unit at the University of Bristol [MC_UU_00032/03]. For the purpose of Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. No funding body has influenced data collection, analysis or interpretation. This publication is the authors' work, who serve as the guarantors for the contents of this paper.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was reviewed and approved by the Independent Scientific Advisory Committee (ISAC), an advisory body for the MHRA. No further patient involvement was required for this study; thus, no additional informed consent was necessary.Study reference ID 21_000362.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes